The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
In this review, the authors provide a comprehensive look at the
technologies behind, for example, ultra-long-acting insulin, and
in-development oral insulin and tissue-selective insulin. It is made
clear how academic research in partnership with the pharmaceutical
industry have allowed for the large-scale production of these refined
insulin analogues.
Looking to the future, the authors outline
how molecular engineering, digitalization and device technology are
poised to enable even more advanced insulin-based therapies such as
glucose-sensitive analogues.
This article includes a narrated video where the authors describe the structural aspects of insulin analog design.
As the authors describe in this perspective featured in the inaugural issue of Nature Communications Medicine, the journey that started with the discovery of insulin has not yet ended. The article outlines the several ground-breaking medical and scientific developments inspired by insulin as a model compound and discusses how future advances in peptide- and protein-based therapies for chronic diseases inarguably can be traced back to the insulin-related advances of the past century.